Category: Pharma News
To create non-viral genetic therapies, Moderna and Generation Bio have formed a strategic partnership.
Moderna, Inc., a biotechnology company that invented messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co., a…
Ionis’ tofersen may be given accelerated approval by the USFDA for SOD1-ALS, according to the advisory committee’s unanimous vote.
Tofersen, an investigational antisense drug for the treatment of people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis,…
When concerns about medication resistance arise, Indian healthcare professionals and pharmaceutical businesses accelerate efforts to treat TB.
When concerns about drug resistance arise, Indian healthcare practitioners and pharmaceutical corporations step up their efforts to control…
Data for the phase 2a first-in-human study of Eyesight RPE for dry AMD will be submitted by Eyestem to DCGI.
The Drugs Controller General of India (DCGI) will receive data from Eyestem for approval of a phase 2a…
The US FDA designates Intellia’s NTLA-2002, a regenerative medicine advanced therapy to treat hereditary angioedema.
The US Food and Drug Administration (FDA) has designated NTLA-2002 for the treatment of hereditary angioedema as a…
To treat patients with solid tumours, Sensei Biotherapeutics has submitted an IND application to the US FDA for a phase 1/2 trial of SNS-101.
An investigational new drug (IND) application for SNS-101, a conditionally active VISTA-blocking antibody, has been submitted to the…
Draft guidelines for the management of urinary bladder cancer are published by the ICMR.
The draught consensus statement for the treatment of urinary bladder cancer has been made public by the Indian…
For the treatment of pancreatic cancer, the US FDA has given Prestige Biopharma’s PBP1510 fast track designation.
The US Food and Drug Administration (FDA) has granted PBP1510 (international non-proprietary name: ulenistamab), a biopharmaceutical product manufactured…
Phase 1 patient dosing of PT886 for advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas is initiated by Phanes Therapeutics.
First patient dosed in phase 1 clinical study (NCT05482893) of PT886, a first-in-class native IgG-like bispecific antibody (bsAb)…
केंद्र D&C अधिनियम और नियमों के उल्लंघन के लिए e-Pharmacy के खिलाफ कार्रवाई करने का दायित्व SLAs पर डालता है|
The Central Government is taking a stand that the sale of medicines should strictly adhere to the provisions…
